Ernexa Therapeutics (ERNAW) Other Non-Current Liabilities (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Other Non-Current Liabilities data on file, last reported at $41000.0 in Q1 2026.

• Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $41000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $43000.0, down 61.26% from the prior year.
• Other Non-Current Liabilities fell to $41000.0 in Q1 2026, from $43000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $13.3 million in Q1 2022 to a low of $41000.0 in Q3 2024.
• A 5-year average of $910823.5 and a median of $87000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 58138.2% in 2022, down 99.75% in 2022.
• Tracing ERNAW's Other Non-Current Liabilities over 5 years: stood at $331000.0 in 2022, then slumped by 74.62% to $84000.0 in 2023, then jumped by 32.14% to $111000.0 in 2024, then plunged by 61.26% to $43000.0 in 2025, then slipped by 4.65% to $41000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $41000.0 (Q1 2026), $43000.0 (Q4 2025), and $112000.0 (Q3 2025), per Business Quant data.